This study was performed to evaluate circulating tumor DNA (ctDNA) kinetics during postoperative radiotherapy (PORT) in patients with residual triple-negative breast cancer (TNBC) at surgery following neoadjuvant chemotherapy (NAC).
Stage II/III patients with post-NAC residual TNBC who required PORT were prospectively included in this study between March 2019 and July 2020. For 11 TNBC patients, next-generation sequencing targeting 38 genes was conducted in 55 samples, including tumor tissue, three plasma samples, and leukocytes from each patient. The plasma samples were collected at three-time points; pre-PORT (T0), after 3 weeks of PORT (T1), and 1 month after PORT (T2). Serial changes in ctDNA variant allele frequency (VAF) were analyzed.
Somatic variants were found in the tumor specimens in 9 out of 11 (81.8%) patients. Mutated genes included TP53 (n = 7); PIK3CA (n = 2); and AKT1, APC, CSMD3, MYC, PTEN, and RB1 (n = 1). These tumor mutations were not found in plasma samples. Plasma ctDNA variants were detected in three (27.3%) patients at T0. Mutations in EGFR (n = 1), CTNNB1 (n = 1), and MAP2K (n = 1) was identified with ctDNA analysis. In two (18.2%) patients, the ctDNA VAF decreased through T1 and T2 while increasing at T2 in one (9.1%) patient. After a median follow-up of 22 months, no patient showed cancer recurrence.
Among patients with post-NAC residual TNBC, more than a quarter exhibited a detectable amount of ctDNA after curative surgery. The ctDNA VAF changed variably during the course of PORT. Therefore, ctDNA kinetics can serve as a biomarker for optimizing adjuvant treatment.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Axillary lymph node
Triple-negative breast cancer
Human epidermal growth factor receptor 2
Complete pathologic response
Minimal residual disease
Circulating tumor DNA
Circulating tumor cells
Disseminated tumor cells
Magnetic resonance imaging
Internal mammary lymph node
Supraclavicular lymph node
Peripheral blood leukocytes
Variant allele frequency
Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, Khan SA, Loibl S, Morris EA, Perez A, Regan MM, Spears PA, Sudheendra PK, Symmans WF, Yung RL, Harvey BE, Hershman DL (2021) Neoadjuvant chemotherapy, endocrine therapy, and targeted Therapy for breast cancer: ASCO guideline. J Clin Oncol 39:1485–1505. https://doi.org/10.1200/JCO.20.03399
Mamtani A, Barrio AV, King TA, Van Zee KJ, Plitas G, Pilewskie M, El-Tamer M, Gemignani ML, Heerdt AS, Sclafani LM, Sacchini V, Cody HS 3rd, Patil S, Morrow M (2016) How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study. Ann Surg Oncol 23:3467–3474. https://doi.org/10.1245/s10434-016-5246-8
Killelea BK, Yang VQ, Mougalian S, Horowitz NR, Pusztai L, Chagpar AB, Lannin DR (2015) Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database. J Am Coll Surg 220:1063–1069. https://doi.org/10.1016/j.jamcollsurg.2015.02.011
Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A, Park KH, Sasano H, Ohashi Y, Toi M (2017) Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 376:2147–2159. https://doi.org/10.1056/NEJMoa1612645
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wulfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr, Investigators K (2019) Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380:617–628. https://doi.org/10.1056/NEJMoa1814017
Murphy BL, Day CN, Hoskin TL, Habermann EB, Boughey JC (2018) Neoadjuvant chemotherapy use in breast cancer is greatest in excellent responders: triple-negative and HER2+ subtypes. Ann Surg Oncol 25:2241–2248. https://doi.org/10.1245/s10434-018-6531-5
Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L (2016) Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 13:674–690. https://doi.org/10.1038/nrclinonc.2016.66
Kennedy WR, Tricarico C, Gabani P, Weiner AA, Altman MB, Ochoa LL, Thomas MA, Margenthaler JA, Sanati S, Peterson LL, Ma CX, Ademuyiwa FO, Zoberi I (2020) Predictors of distant metastases in triple-negative breast cancer without p complete response after neoadjuvant chemotherapy. J Natl Compr Canc Netw 18:288–296. https://doi.org/10.6004/jnccn.2019.7366
Kern P, Von Minckwitz G, Puetter C, Pavlidou S, Flach A, Kimmig R, Rezai M (2015) Prognostic impact of residual disease after neoadjuvant chemotherapy in 648 patients with triple-negative breast cancer. Anticancer Res 35:5479–5484
Hall C, Karhade M, Laubacher B, Anderson A, Kuerer H, DeSynder S, Lucci A (2015) Circulating tumor cells after neoadjuvant chemotherapy in stage I-III triple-negative breast cancer. Ann Surg Oncol 22(Suppl 3):S552-558. https://doi.org/10.1245/s10434-015-4600-6
Ben Lassoued A, Nivaggioni V, Gabert J (2014) Minimal residual disease testing in hematologic malignancies and solid cancer. Expert Rev Mol Diagn 14:699–712. https://doi.org/10.1586/14737159.2014.927311
Goodman CR, Speers CW (2021) The role of circulating tumor cells in breast cancer and implications for radiation treatment decisions. Int J Radiat Oncol Biol Phys 109:44–59. https://doi.org/10.1016/j.ijrobp.2020.08.039
Openshaw MR, Page K, Fernandez-Garcia D, Guttery D, Shaw JA (2016) The role of ctDNA detection and the potential of the liquid biopsy for breast cancer monitoring. Expert Rev Mol Diagn 16:751–755. https://doi.org/10.1080/14737159.2016.1184974
Mignot F, Loirat D, Dureau S, Bataillon G, Caly M, Vincent-Salomon A, Berger F, Fourquet A, Pierga JY, Kirova YM, Bidard FC (2019) Disseminated tumor cells predict efficacy of regional nodal irradiation in early stage breast cancer. Int J Radiat Oncol Biol Phys 103:389–396. https://doi.org/10.1016/j.ijrobp.2018.09.033
Goodman CR, Seagle BL, Friedl TWP, Rack B, Lato K, Fink V, Cristofanilli M, Donnelly ED, Janni W, Shahabi S, Strauss JB (2018) Association of circulating tumor cell status with benefit of radiotherapy and survival in early-stage breast cancer. JAMA Oncol 4:e180163. https://doi.org/10.1001/jamaoncol.2018.0163
Newman AM, Lovejoy AF, Klass DM, Kurtz DM, Chabon JJ, Scherer F, Stehr H, Liu CL, Bratman SV, Say C, Zhou L, Carter JN, West RB, Sledge GW, Shrager JB, Loo BW Jr, Neal JW, Wakelee HA, Diehn M, Alizadeh AA (2016) Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol 34:547–555. https://doi.org/10.1038/nbt.3520
McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA (2010) The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20:1297–1303. https://doi.org/10.1101/gr.107524.110
Li H (2011) A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data. Bioinformatics 27:2987–2993. https://doi.org/10.1093/bioinformatics/btr509
Shin SH, Kim YJ, Lee D, Cho D, Ko YH, Cho J, Park WY, Park D, Kim SJ, Kim WS (2019) Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes. Leuk Lymphoma 60:2237–2246. https://doi.org/10.1080/10428194.2019.1573998
De Michino S, Aparnathi M, Rostami A, Lok BH, Bratman SV (2020) The utility of liquid biopsies in radiation oncology. Int J Radiat Oncol Biol Phys 107:873–886. https://doi.org/10.1016/j.ijrobp.2020.05.008
Janni WJ, Rack B, Terstappen LW, Pierga JY, Taran FA, Fehm T, Hall C, de Groot MR, Bidard FC, Friedl TW, Fasching PA, Brucker SY, Pantel K, Lucci A (2016) Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer. Clin Cancer Res 22:2583–2593. https://doi.org/10.1158/1078-0432.CCR-15-1603
Trapp E, Janni W, Schindlbeck C, Juckstock J, Andergassen U, de Gregorio A, Alunni-Fabbroni M, Tzschaschel M, Polasik A, Koch JG, Friedl TWP, Fasching PA, Haeberle L, Fehm T, Schneeweiss A, Beckmann MW, Pantel K, Mueller V, Rack B, Scholz C, Group SS (2019) Presence of circulating tumor cells in high-risk early breast cancer during follow-up and prognosis. J Natl Cancer Inst 111:380–387. https://doi.org/10.1093/jnci/djy152
Cavallone L, Aguilar-Mahecha A, Lafleur J, Brousse S, Aldamry M, Roseshter T, Lan C, Alirezaie N, Bareke E, Majewski J, Ferrario C, Hassan S, Discepola F, Seguin C, Mihalcioiu C, Marcus EA, Robidoux A, Roy JA, Pelmus M, Basik M (2020) Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer. Sci Rep 10:14704. https://doi.org/10.1038/s41598-020-71236-y
Magbanua MJM, Swigart LB, Wu HT, Hirst GL, Yau C, Wolf DM, Tin A, Salari R, Shchegrova S, Pawar H, Delson AL, DeMichele A, Liu MC, Chien AJ, Tripathy D, Asare S, Lin CJ, Billings P, Aleshin A, Sethi H, Louie M, Zimmermann B, Esserman LJ, van ’t Veer LJ, (2021) Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann Oncol 32:229–239. https://doi.org/10.1016/j.annonc.2020.11.007
Radovich M, Jiang G, Hancock BA, Chitambar C, Nanda R, Falkson C, Lynce FC, Gallagher C, Isaacs C, Blaya M, Paplomata E, Walling R, Daily K, Mahtani R, Thompson MA, Graham R, Cooper ME, Pavlick DC, Albacker LA, Gregg J, Solzak JP, Chen YH, Bales CL, Cantor E, Shen F, Storniolo AMV, Badve S, Ballinger TJ, Chang CL, Zhong Y, Savran C, Miller KD, Schneider BP (2020) Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer: preplanned secondary analysis of the BRE12-158 randomized clinical trial. JAMA Oncol 6:1410–1415. https://doi.org/10.1001/jamaoncol.2020.2295
Cullinane C, Fleming C, O’Leary DP, Hassan F, Kelly L, O’Sullivan MJ, Corrigan MA, Redmond HP (2020) Association of circulating tumor DNA with disease-free survival in breast cancer: a systematic review and meta-analysis. JAMA Netw Open 3:e2026921. https://doi.org/10.1001/jamanetworkopen.2020.26921
Chen YH, Hancock BA, Solzak JP, Brinza D, Scafe C, Miller KD, Radovich M (2017) Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy. NPJ Breast Cancer 3:24. https://doi.org/10.1038/s41523-017-0028-4
Madsen EV, Aalders KC et al (2015) Prognostic significance of tumor-positive internal mammary sentinel lymph nodes in breast cancer: a multicenter cohort study. Ann Surg Oncol 22:4254–4262. https://doi.org/10.1245/s10434-015-4535-y
Dellapasqua S, Bagnardi V, Balduzzi A, Iorfida M, Rotmensz N, Santillo B, Viale G, Ghisini R, Veronesi P, Luini A, Morra A, Goldhirsch A, Colleoni M (2014) Outcomes of patients with breast cancer who present with ipsilateral supraclavicular or internal mammary lymph node metastases. Clin Breast Cancer 14:53–60. https://doi.org/10.1016/j.clbc.2013.09.008
Kim H, Kim SS, Lee IJ, Shin KH, Kim K, Jung J, Kim YB, Chang JS, Choi DH, Park W, Yang K, Chang JH, Cha J, Kim JH, Lee DS (2021) Outcome of radiotherapy for clinically overt metastasis to the internal mammary lymph node in patients receiving neoadjuvant chemotherapy and breast cancer surgery. Breast 55:112–118. https://doi.org/10.1016/j.breast.2020.12.011
Olivotto IA, Chua B, Allan SJ, Speers CH, Chia S, Ragaz J (2003) Long-term survival of patients with supraclavicular metastases at diagnosis of breast cancer. J Clin Oncol 21:851–854. https://doi.org/10.1200/JCO.2003.11.105
Kim K, Jeong Y, Shin KH, Kim JH, Ahn SD, Kim SS, Suh CO, Kim YB, Choi DH, Park W, Cha J, Chun M, Lee DS, Lee SY, Kim JH, Park HJ, Jung W (2019) Impact of regional nodal irradiation for breast cancer patients with supraclavicular and/or internal mammary lymph node involvement: a multicenter, retrospective study (KROG 16–14). Cancer Res Treat 51:1500–1508. https://doi.org/10.4143/crt.2018.575
Li S, Lai H, Liu J, Liu Y, Jin L, Li Y, Liu F, Gong Y, Guan Y, Yi X, Shi Q, Cai Z, Li Q, Li Y, Zhu M, Wang J, Yang Y, Wei W, Yin D, Song E, Liu Q (2020) Circulating tumor DNA predicts the response and prognosis in patients with early breast cancer receiving neoadjuvant chemotherapy. JCO Precis Oncol. https://doi.org/10.1200/PO.19.00292
Magbanua MJM, Swigart LB, Wu HT, Hirst GL, Yau C, Wolf DM, Tin A, Salari R, Shchegrova S, Pawar H, Delson AL, DeMichele A, Liu MC, Chien AJ, Tripathy D, Asare S, Lin CHJ, Billings P, Aleshin A, Sethi H, Louie M, Zimmermann B, Esserman LJ, van’t Veer LJ (2021) Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann Oncol 32:229–239. https://doi.org/10.1016/j.annonc.2020.11.007
Bratman SV, Yang SYC, Iafolla MAJ, Liu Z, Hansen AR, Bedard PL, Lheureux S, Spreafico A, Razak AA, Shchegrova S, Louie M, Billings P, Zimmermann B, Sethi H, Aleshin A, Torti D, Marsh K, Eagles J, Cirlan I, Hanna Y, Clouthier DL, Lien SC, Ohashi PS, Xu W, Siu LL, Pugh TJ (2020) Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat Cancer 1:873–881. https://doi.org/10.1038/s43018-020-0096-5
Keller L, Belloum Y, Wikman H, Pantel K (2021) Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. Br J Cancer 124:345–358. https://doi.org/10.1038/s41416-020-01047-5
This study was supported by grants from the Ministry of Science and ICT, Republic of Korea (NRF-2019R1F1A1062069) and Samsung Medical Center (SMO 1200821 and SMO 1200391). The funding sources had no involvement in the study design, data collection, data analysis, data interpretation, writing of this report, or the decision to submit this article for publication.
Conflict of interest
The authors declare that they have no competing interests.
Ethics approval and consent to participate
All patients provided consents to participate. This study was approved by the institutional review board of the Samsung Medical Center (approval number, SMC 2018-10-137-009).
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This study was presented as a poster at the 17th St. Gallen International Breast Cancer Conference on March 17, 2021.
About this article
Cite this article
Kim, H., Kim, Y.J., Park, D. et al. Dynamics of circulating tumor DNA during postoperative radiotherapy in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: a prospective observational study. Breast Cancer Res Treat 189, 167–175 (2021). https://doi.org/10.1007/s10549-021-06296-3
- Circulating tumor DNA
- Breast neoplasms
- Triple Negative Breast Neoplasms